LSD1-CoREST

Beyond's analysis on LSD1-CoREST

• 2026-09-22 — Beactica Therapeutics advances novel LSD1-CoREST degrader for glioblastoma into IND-enabling phase

Recent news mentioning LSD1-CoREST

• 2026-09-22 — Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma
• 2026-09-22 — Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma

Appears alongside

• Beactica Therapeutics
• IND-enabling
• BEA-17

Browse the full archive →